AIM ImmunoTech CEO to Participate in Virtual Investor Fireside Chat on Dec 4th
ByAinvest
Monday, Dec 1, 2025 8:57 am ET1min read
AIM--
AIM ImmunoTech's CEO, Thomas Equels, will participate in a virtual investor event on Dec. 4, discussing the company's clinical and regulatory strategy for its lead drug Ampligen and its ongoing DURIPANC clinical trial with AstraZeneca. Equels will also discuss a completed Phase 2 clinical trial with Merck, which found that Ampligen combined with Keytruda was well-tolerated and demonstrated clinical benefit in treating advanced ovarian cancer. The event will be livestreamed on the company's website.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet